×
Please click
here
if you are not redirected within a few seconds.
All
News
Maps
Images
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript
Yahoo Finance
AbCellera Biologics Inc. (NASDAQ:ABCL) Q1 2024 Earnings Call Transcript May 7, 2024 AbCellera Biologics Inc. isn't one of the 30 most...
2 weeks ago
AbCellera and Biogen link on neurological antibody therapy
Pharmaceutical Technology
AbCellera has entered into a partnership with Biogen to discover therapeutic antibodies for treating neurological ailments.
2 months ago
AbCellera Biologics Inc (ABCL) Q1 2024 Earnings: Misses Revenue and Net Loss Estimates
Yahoo Finance
Revenue: Reported at $10.0 million, down from $12.2 million in Q1 2023, falling short of the estimated $10.84 million.
2 weeks ago
AbCellera Biologics (NASDAQ:ABCL) Hits New 12-Month Low at $3.58
MarketBeat
AbCellera Biologics Inc. (NASDAQ:ABCL - Get Free Report) hit a new 52-week low on Monday . The stock traded as low as $3.58 and last traded...
1 day ago
AbCellera Stock: Cash Providing Shelter From Market Weakness (NASDAQ:ABCL)
Seeking Alpha
AbCellera Biologics is a drug discovery company focused on developing antibody therapies. While the company has developed a technology...
6 days ago
AbCellera Biologics (ABCL) Q1 2024 Earnings Call Transcript
The Motley Fool
AbCellera Biologics (ABCL -3.70%) Q1 2024 Earnings Call May 07, 2024, 5:00 p.m. ET. Contents: Prepared Remarks; Questions and Answers...
2 weeks ago
Analysts Estimate AbCellera Biologics Inc. (ABCL) to Report a Decline in Earnings: What to Look Out for
Zacks Investment Research
AbCellera Biologics (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming...
3 weeks ago
In the wake of AbCellera Biologics Inc.'s (NASDAQ:ABCL) latest US$91m market cap drop, institutional owners may be forced to take severe actions
Simply Wall Street
It looks like hedge funds own 7.8% of AbCellera Biologics shares. That's interesting, because hedge funds can be quite active and activist. Many...
1 month ago
AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Misses Revenue Estimates
Yahoo Finance
AbCellera Biologics Inc. (ABCL) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.16.
2 weeks ago
Insider Stock Buying Reaches US$1.61m On AbCellera Biologics
Yahoo Finance
Quite a few insiders have dramatically grown their holdings in AbCellera Biologics Inc. ( NASDAQ:ABCL ) over the past...
3 weeks ago